A report on the business newswire Bloomberg could have implications for a class action lawsuit approved a month ago by the Ontario Superior Court of Justice.
According to court documents filed in a suit brought by the state of Alaska, Bloomberg says, the drug company "Eli Lilly & Co. trained its sales force to downplay risks for Zyprexa and encourage doctors to prescribe the drug beyond approved uses for schizophrenia and bipolar disorder."
The story says Lily's own research found that "some patients on Zyprexa gained as much as 80 pounds and that the incidence of high blood sugar at diabetes levels was 3.5 times higher than for placebos."
